CytoGenix, Inc. a biotech company that develops products for vaccines and therapeutic applications, has a new CFO. The company operates in human, agricultural and veterinary markets. The new Chief Financial Officer is Steven M. Plumb.
Steven M. Plumb is a CPA with more than 25 years of accounting experience. He has been a full-time employee and a consultant is technology, health care, and biotech industries.
Most recently, he was president of Clear Financial Solutions, Inc. the business consulting firm he founded in 2001.
Mr Plumb replaces Randy Moseley, who just resigned as Chief Financial Officer and Chairman of the Board of CytoGenix.
CytoGenix CEO, Lex Cowsert said the company applauded Steven Plumb’s uncompromising integrity, leadership, ingenuity, tenacity and flawless execution with some of the most respected accounting and pharmaceutical companies in the world.
“As our new Chief Financial Officer, Steven Plumb will bring all these qualities to CytoGenix as we continue to develop and continue to commercialize various Life Science and Energy related Bio-technologies while working to build a successful company. The vote of confidence that Steven Plumb has demonstrated by joining our executive team validates our course of action and strategic vision.”
– CytoGenix CEO, Lex Cowsert
Plumb served as CFO for public companies, including Striker Oil & Gas, Inc., Oncolin Therapeutics, Inc., Hyperdynamics Corp., Bluegate Corp., and Adventrx Pharmaceuticals, Inc. He was also Chief Financial Officer of two private companies that he co-founded, HoustonPharma, Inc. and 3A Pharma, LLC.
Steven Plumb said, “I am honored and excited about this new role at CytoGenix. … I am looking forward to working with this team of key people, with such an uncompromising will to create and succeed.”
Mr. Plumb is a Certified Public Account and a member of the American Institute of Certified Public Accounts. He earned a BBA degree in accounting from the University of Texas at Austin.
